ArticleScientific reports2025
Rapid screening for acute rheumatic fever using machine learning analysis of host tissue reactive antibodies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Acute Rheumatic Fever and Rheumatic Heart Disease (ARF/RHD) affect over 45 million people globally. ARF/RHD are autoimmune complications following group A streptococcal infections. Current diagnosis of ARF requires thorough medical examination, echocardiography and laboratory tests that are unavailable in most primary care settings where patients with ARF typically first present. This pilot study was conducted to determine whether machine learning-based predictive models could be used to stratify host tissue protein reactive antibodies associated with ARF, that could be incorporated into a lateral flow point-of-care (POC) platform for ARF screening. We investigated serum antibody levels against four host tissue proteins (cardiac myosin, laminin, keratin, and tropomyosin) known to increase in ARF. Serum samples were obtained from: (i) a rat autoimmune valvulitis model (RAV) of RHD (30 streptococcal M protein-injected rats versus 30 controls); and (ii) human samples (25 newly diagnosed ARF patients versus 50 healthy controls). Four machine learning algorithms (logistic regression, decision tree, random forest, and AdaBoost) predicted ARF status using antibody levels detected by enzyme-linked immunosorbent assay (ELISA). Rats injected with streptococcal M protein developed cardiac pathology and demonstrated three-fold higher optical density values for all four host tissue protein reactive antibodies compared to controls. ARF patients showed significantly elevated antibody levels against all host tissue proteins tested (p < 0.01). Random forest achieved optimal performance for rat data (sensitivity 100%, specificity 92.5%, AUROC = 0.97), while AdaBoost excelled for human samples using binary biomarkers (sensitivity 85.0%, specificity 82.8%, AUROC = 0.87). We demonstrate the screening potential of known host tissue protein reactive antibodies and propose lateral flow assay POC technology as a possible advancement toward improved early screening for ARF in resource-constrained environments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.